Globe Newswire09.14.20
Neuronetics Inc., a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric disorders, announced that Keith J. Sullivan has been appointed as the company’s president and CEO and has joined the Board of Directors effective immediately.
“The Neuronetics Board of Directors is very happy to complete our rigorous CEO search with the hiring of Keith Sullivan. Keith’s track record includes successfully growing multiple medtech businesses, driving innovation and impressive market development,” said Brian Farley, Neuronetics’ board chairman. “We believe that Keith’s experience in commercializing products that involve both capital equipment and recurring revenue streams is an excellent fit with Neuronetics, and I am confident his public company experience and leadership skills further position Neuronetics extremely well for strong execution.”
Sullivan brings over three decades of medical device industry experience to the company. He most recently served as chief commercial officer and president (North America) of ZELTIQ Aesthetics Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform under the Coolsculpting brand, from January 2016 until the acquisition of ZELTIQ by Allergan Inc. in April 2017. Sullivan previously served as senior vice president and chief commercial officer of ZELTIQ from November 2014 until January 2016 and as senior vice president of Worldwide Sales and Marketing from July 2013 through October 2014. Sullivan, who has more than 30 years of senior sales leadership experience in the medical device industry, has previously held leadership positions with Medicis Pharmaceuticals, Reliant Technologies, Medtronic plc, Vision Quest Laser Center, and Coherent Medical.
Sullivan earned a bachelor's degree in business administration from the College of William and Mary and is a clinical professor in the Mason School of Business at William and Mary. Sullivan currently serves on the Boards of Directors of Sientra Inc. and Venus Concept.
“I am very excited to join Neuronetics and work with the team to reinvigorate our business, optimize our go to market strategy, drive innovation and deliver premier service to our customers and the patients they treat. Mental health is so important, and the COVID-19 pandemic has brought to the forefront the debilitating impact of depression on individuals and society as a whole,” said Sullivan. “It is a privilege to join a company with the critically important mission of renewing lives by transforming neurohealth. I have been thoroughly impressed by the strength and caliber of the Neuronetics team and the Board of Directors. I look forward to capitalizing on the significant opportunities ahead.”
Farley concluded, “The Board is grateful to the office of the president, Steve Furlong, CFO, and Andy Macan, general counsel, as well as the rest of the executive team for leading the company during the CEO transition and guiding the company through the COVID-19 pandemic. We are pleased that the company has weathered these past four months so well in the face of such tremendous challenges.”
“The Neuronetics Board of Directors is very happy to complete our rigorous CEO search with the hiring of Keith Sullivan. Keith’s track record includes successfully growing multiple medtech businesses, driving innovation and impressive market development,” said Brian Farley, Neuronetics’ board chairman. “We believe that Keith’s experience in commercializing products that involve both capital equipment and recurring revenue streams is an excellent fit with Neuronetics, and I am confident his public company experience and leadership skills further position Neuronetics extremely well for strong execution.”
Sullivan brings over three decades of medical device industry experience to the company. He most recently served as chief commercial officer and president (North America) of ZELTIQ Aesthetics Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform under the Coolsculpting brand, from January 2016 until the acquisition of ZELTIQ by Allergan Inc. in April 2017. Sullivan previously served as senior vice president and chief commercial officer of ZELTIQ from November 2014 until January 2016 and as senior vice president of Worldwide Sales and Marketing from July 2013 through October 2014. Sullivan, who has more than 30 years of senior sales leadership experience in the medical device industry, has previously held leadership positions with Medicis Pharmaceuticals, Reliant Technologies, Medtronic plc, Vision Quest Laser Center, and Coherent Medical.
Sullivan earned a bachelor's degree in business administration from the College of William and Mary and is a clinical professor in the Mason School of Business at William and Mary. Sullivan currently serves on the Boards of Directors of Sientra Inc. and Venus Concept.
“I am very excited to join Neuronetics and work with the team to reinvigorate our business, optimize our go to market strategy, drive innovation and deliver premier service to our customers and the patients they treat. Mental health is so important, and the COVID-19 pandemic has brought to the forefront the debilitating impact of depression on individuals and society as a whole,” said Sullivan. “It is a privilege to join a company with the critically important mission of renewing lives by transforming neurohealth. I have been thoroughly impressed by the strength and caliber of the Neuronetics team and the Board of Directors. I look forward to capitalizing on the significant opportunities ahead.”
Farley concluded, “The Board is grateful to the office of the president, Steve Furlong, CFO, and Andy Macan, general counsel, as well as the rest of the executive team for leading the company during the CEO transition and guiding the company through the COVID-19 pandemic. We are pleased that the company has weathered these past four months so well in the face of such tremendous challenges.”